certolizumab pegol

Ligand id: 6774

Name: certolizumab pegol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: certolizumab pegol

Immunopharmacology Comments
By neutralising TNFα (soluble and membrane forms), certolizumab pegol disrupts production of pro-inflammatory cytokines such as IL-1β, and this action underlies its effectiveness in treating autoimmune diseases.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
An anti-TNFα therapy approved for RA.
Crohn's disease Disease Ontology: DOID:8778
OMIM: 266600
Orphanet: ORPHA206
An anti-TNFα therapy approved for CD.
Axial spondyloarthritis Approved drug for axial spondyloarthritis (EMA 2009)
Psoriasis Disease Ontology: DOID:8893
Approved drug for moderate-to-severe plaque psoriasis (FDA 2018) and psoriatic arthritis (EMA 2009).